Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Page 1
Therapies in Stiff-Person Syndrome: Advances and Future Prospects Based on Disease Pathophysiology.
Dalakas MC. Dalakas MC. Neurol Neuroimmunol Neuroinflamm. 2023 Apr 14;10(3):e200109. doi: 10.1212/NXI.0000000000200109. Print 2023 May. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 37059468 Free PMC article. Review.
A practical, step-by-step therapeutic approach is provided, highlighting the importance of combination therapies with the preferred gamma-aminobutyric acid-enhancing antispasmodic drugs, such as baclofen, tizanidine, benzodiazepines, and gabapentin, that provide the first-line sy …
A practical, step-by-step therapeutic approach is provided, highlighting the importance of combination therapies with the preferred gamma-am …
First-line disease modifying treatments in pediatric-onset multiple sclerosis in Greece: therapy initiation at more advanced age is the main cause of treatment failure, in a retrospective observational study, with a cohort from a single Multiple Sclerosis Center.
Skarlis C, Markoglou N, Gontika M, Bougea A, Katsavos S, Artemiadis A, Chrousos G, Dalakas M, Stefanis L, Anagnostouli M. Skarlis C, et al. Among authors: dalakas m. Neurol Sci. 2023 Feb;44(2):693-701. doi: 10.1007/s10072-022-06431-y. Epub 2022 Oct 5. Neurol Sci. 2023. PMID: 36197577 Free PMC article.
OBJECTIVES: Long-term immunomodulatory therapy of pediatric onset-multiple sclerosis (POMS) is based mainly on published case series and internationally agreed guidelines. ...
OBJECTIVES: Long-term immunomodulatory therapy of pediatric onset-multiple sclerosis (POMS) is based mainly on published case series …
Long-term Effectiveness of IVIg Maintenance Therapy in 36 Patients With GAD Antibody-Positive Stiff-Person Syndrome.
Yi J, Dalakas MC. Yi J, et al. Among authors: dalakas mc. Neurol Neuroimmunol Neuroinflamm. 2022 Jul 7;9(5):e200011. doi: 10.1212/NXI.0000000000200011. Print 2022 Sep. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 35798561 Free PMC article.
The present study explores the long-term effects of IVIg in the largest cohort of well-characterized patients with SPS followed by the same clinicians over 10 years. ...DISCUSSION: This is a large study in 36 patients with SPS demonstrating that monthly maintenance IVIg th …
The present study explores the long-term effects of IVIg in the largest cohort of well-characterized patients with SPS followed by th …
Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis.
Dalakas MC. Dalakas MC. Expert Rev Clin Immunol. 2022 Jul;18(7):691-701. doi: 10.1080/1744666X.2022.2082946. Epub 2022 Jun 23. Expert Rev Clin Immunol. 2022. PMID: 35730504
Indeed, the anti-C5 monoclonal antibodies, Eculizumab, Ravulizumab, and Zilucoplan, have been successfully tested in MG with Eculizumab first and now Ravulizumab FDA-approved for refractory MG based on sustained long-term benefits. Among the biologics that inhibit FcRn, Ef …
Indeed, the anti-C5 monoclonal antibodies, Eculizumab, Ravulizumab, and Zilucoplan, have been successfully tested in MG with Eculizumab firs …
Progressive multifocal fibrosing neuropathy: description of a novel disease.
Mendoza FA, Bagley J, Gochfeld M, Dalakas MC, Farber JL, Jimenez SA. Mendoza FA, et al. Among authors: dalakas mc. Acta Neuropathol Commun. 2022 Mar 16;10(1):34. doi: 10.1186/s40478-022-01341-8. Acta Neuropathol Commun. 2022. PMID: 35296359 Free PMC article.
We suggest that the clinical findings described here represent a previously undescribed fibrotic disorder affecting peripheral nerves, and we propose the descriptive term "Progressive Multifocal Fibrosing Neuropathy" to refer to this novel disorder. ...
We suggest that the clinical findings described here represent a previously undescribed fibrotic disorder affecting peripheral nerves, and w …
Autoimmune Neurological Disorders with IgG4 Antibodies: a Distinct Disease Spectrum with Unique IgG4 Functions Responding to Anti-B Cell Therapies.
Dalakas MC. Dalakas MC. Neurotherapeutics. 2022 Apr;19(3):741-752. doi: 10.1007/s13311-022-01210-1. Epub 2022 Mar 15. Neurotherapeutics. 2022. PMID: 35290608 Free PMC article. Review.
Because the IgG4 antibodies do not trigger inflammatory processes or complement-mediated immune responses, the conventional anti-inflammatory therapies, especially with IVIg, immunosuppressants, and plasmapheresis, are ineffective or not sufficiently effective in inducing long- …
Because the IgG4 antibodies do not trigger inflammatory processes or complement-mediated immune responses, the conventional anti-inflammator …
Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases.
Stathopoulos P, Dalakas MC. Stathopoulos P, et al. Among authors: dalakas mc. Neurotherapeutics. 2022 Apr;19(3):691-710. doi: 10.1007/s13311-022-01196-w. Epub 2022 Feb 18. Neurotherapeutics. 2022. PMID: 35182380 Free PMC article. Review.
The efficacy of the various anti-B cell therapies and practical issues on induction and maintenance therapy is specifically detailed for the treatment of patients with multiple sclerosis, neuromyelitis-spectrum disorders, autoimmune encephalitis and hyperexcitability CNS disorder …
The efficacy of the various anti-B cell therapies and practical issues on induction and maintenance therapy is specifically detailed for the …
Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies.
Dalakas MC. Dalakas MC. Curr Opin Neurol. 2020 Oct;33(5):545-552. doi: 10.1097/WCO.0000000000000858. Curr Opin Neurol. 2020. PMID: 32833750 Review.
Most patients with MuSK-positive myasthenia gravis treated with Rituximab have sustained long-term remission with persistent reduction of IgG4 anti-MuSK antibodies. Eculizumb in the extension REGAIN study showed sustained long-term pharmacological remissions and red …
Most patients with MuSK-positive myasthenia gravis treated with Rituximab have sustained long-term remission with persistent reductio …
Trial of canakinumab, an IL-1β receptor antagonist, in patients with inclusion body myositis.
Kosmidis ML, Pikazis D, Vlachoyiannopoulos P, Tzioufas AG, Dalakas MC. Kosmidis ML, et al. Among authors: dalakas mc. Neurol Neuroimmunol Neuroinflamm. 2019 Jun 10;6(4):e581. doi: 10.1212/NXI.0000000000000581. eCollection 2019 Jul. Neurol Neuroimmunol Neuroinflamm. 2019. PMID: 31355317 Free PMC article.
In patients 2 and 4, in whom 3-year longitudinal data were available, no effect on disease progression was noted. CONCLUSIONS: In this long-term, open-label study, canakinumab showed small, but not clinically appreciable, stabilizing benefits in 2 of 5 patients with sIBM o …
In patients 2 and 4, in whom 3-year longitudinal data were available, no effect on disease progression was noted. CONCLUSIONS: In this long- …
Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies.
Dalakas MC. Dalakas MC. Ther Adv Neurol Disord. 2018 Jan 15;11:1756285617746640. doi: 10.1177/1756285617746640. eCollection 2018. Ther Adv Neurol Disord. 2018. PMID: 29403542 Free PMC article. Review.
Open-label studies in >200 patients indicate that rituximab is helpful in 30-50% of these patients, even with long-term benefits, probably by suppressing IgM anti-MAG antibodies or inducing immunoregulatory T cells. ...
Open-label studies in >200 patients indicate that rituximab is helpful in 30-50% of these patients, even with long-term benefits, …
42 results